Loading...
•
Dec 31, 2024
Repligen Q4 2024 Earnings Report
Repligen reported its Q4 2024 earnings, highlighting revenue growth, strong order momentum, and restructuring impacts.
Key Takeaways
Repligen posted Q4 2024 revenue of $168 million, up 1% year-over-year. Adjusted EPS was $0.44, down from $0.48 in Q4 2023. The company reported a GAAP net loss of $34 million due to restructuring costs, but adjusted net income reached $25 million. Order growth in CDMO and capital equipment segments drove optimism for 2025.
Q4 revenue increased 1% year-over-year to $168 million.
GAAP net loss of $34 million, impacted by restructuring charges.
Adjusted EPS came in at $0.44, down from $0.48 in Q4 2023.
Strong order momentum in CDMO and capital equipment segments.
Revenue by Segment
Forward Guidance
Repligen expects 8-12% reported revenue growth for FY 2025, driven by strong order momentum and CDMO expansion, while facing challenges from restructuring costs and currency headwinds.
Positive Outlook
- Forecasted revenue growth of 8-12% for FY 2025.
- Expected non-COVID revenue growth of 10-14%.
- Continued strong demand from CDMO and capital equipment markets.
- Launch of innovative AVIPure dsRNA resin for mRNA-based therapies.
- Recent Tantti Laboratory acquisition strengthens chromatography offerings.
Challenges Ahead
- Continued macroeconomic uncertainty in biotech investments.
- Restructuring costs impacting short-term profitability.
- Currency headwinds affecting international revenue.
- Competitive pressure in the bioprocessing sector.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...